❓How will #aducanumab’s approval influence people’s willingness to join, and stay in, future Alzheimer’s disease #clinicaltrials? UCI MIND Director Joshua Grill, PhD was recently quoted by Alzforum discussing this topic. Read more about UCI MIND #InTheNews: https://www.alzforum.org/news/conference-coverage/aduhelm-approval-reverberates-through-research
Read More
Karen Zagorski of the Institute for Molecular Medicine in Huntington Beach presented data on a line of research conducted in collaboration with UCI MIND’s David Cribbs, Hayk Davtyan, and Matt Blurton-Jones.
Read More
NIA-supported scientists have developed a new mouse model that produces a form of the human beta-amyloid protein, a hallmark of Alzheimer’s disease. An important research tool, mouse models enable the exploration of genetic, environmental, and behavioral aspects of Alzheimer’s, as well as make it possible to test drug candidates before human studies. The new mouse model, which was reported in a recent article in Nature Communications, can be used by other scientists to advance Alzheimer’s research. Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) MODEL-AD consortium Many factors, including gene changes, the aging process, and conditions in the…
Read More
UCI MIND at #AAIC María M. Corrada, ScM, ScD contributes: In The Life After 90 Study, a one-of-a-kind multiethnic cohort of individuals 90 and older, memory concerns appear to identify individuals with objective cognitive impairment but do not identify those whose cognition may decline faster. With additional enrollment and longer follow-up, we will continue to explore the utility of memory concerns in predicting future cognitive performance and potential ethnoracial differences in a segment of the population that is often excluded from research.
Read More
UCI MIND Director, Joshua Grill, PhD spoke today as part of a panel on the impact of drug approval on future clinical trials at the AAIC Annual Conference in Denver, CO. Dr. Grill presented on the ethical considerations needed for designing studies in the presence of an approved drug like Aduhelm. To learn more about this topic, read the recent paper he co-authored with Dr. Jason Karlawish in Neurology
Read More
UCI MIND professor, David Sultzer, MD, and other investigators show a clinical benefit of an investigational antipsychotic drug, pimavanserin in reducing behavioral symptoms related to Alzheimer's disease. David Sultzer, MD, Professor, Psychiatry & Human Behavior, School of Medicine
Read More
UCI MIND researcher, Dr. Vivek Swarup is gaining significant attention for his work on glial cell gene expression in AD. His lab’s research, published in Nature Genetics 2 weeks ago was recently featured on the heavily trafficked Alzheimer’s research website, Alzforum.com – a testament to the impact his research has on the broader AD community. Dr. Swarup used prefrontal cortex brain tissue from UCI ADRC brain donors to examine differences in glial cell gene transcription between healthy and AD brains. He found that the areas in the DNA above important AD risk genes, responsible for expressing those genes, were different…
Read More
Sept. 10th Virtual Alzheimer's Research Conference #AlzAngles: Dr. Thomas Lane will discuss the impact of viral infections, like COVID-19, on Alzheimer’s disease. Register for free: https://conference.mind.uci.edu/register
Read More
Contributed by Joshua Grill, PhD and Jason Karlawish, MD UCI MIND Director Joshua Grill, PhD co-authored an article in Nature Reviews Neurology about the FDA's decision on Aduhelm. Read more on this below: Since the FDA approved Aduhelm (aducanumab) on June 7, there has been considerable conversation, debate, and even backlash about the decision. It may seem difficult to keep up. Here is a recap of some of the most recent important events. The FDA granted Aduhelm what is known as “accelerated approval.” This means that the approval did not indicate that the drug has been adequately shown to benefit…
Read More
UCI School of Biological Sciences Dean Frank LaFerla is co-senior author of a study involving a new genetically engineered mouse model that, unlike its predecessors, is based on the most common form of Alzheimer’s disease. This could help lead to major strides in the fight to end this deadly disease! Dean LaFerla discusses his findings in a new podcast: https://www.bio.uci.edu/frank-laferla-podcast/
Read More
